Results 281 to 290 of about 28,689 (318)

Therapeutic Drug Monitoring for Precision Dosing of Janus Kinase Inhibitors: Protocol for a Prospective Observational Study.

JMIR Res Protoc
Tachet J, Decosterd LA, Guidi M, Girardin FR.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis

Expert Review of Hematology, 2022
Myelofibrosis (MF) is characterized by ineffective and hepatosplenic extramedullary hematopoiesis due to fibrotic changes in the bone marrow and systemic manifestations due to aberrant cytokine release. Ruxolitinib (RUX) is the first JAK1/JAK2 inhibitor that is clinically approved to treat splenomegaly by ameliorating inflammatory cytokines and ...
Dong Won, Baek, Hee Jeong, Cho, Jung Min, Lee, Juhyung, Kim, Joon Ho, Moon, Sang Kyun, Sohn   +5 more
openaire   +2 more sources

Ruxolitinib (Jakavi)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Jakavi be reimbursed by public drug plans for the treatment of steroid-refractory or steroid-dependent acute graft-versus-host disease (aGvHD) if certain conditions are met. Jakavi should only be covered to treat adults and pediatric patients aged 12 years and older who have steroid-refractory or steroid-dependent ...
openaire   +1 more source

Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge

Annals of Hematology, 2014
n ...
PALANDRI, FRANCESCA, POLVERELLI, NICOLA, CATANI, LUCIA, VIANELLI, NICOLA   +3 more
openaire   +2 more sources

Ruxolitinib

2018
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis (MF) by the US Food and Drug Administration (FDA) in 2011 and by the European Medicines Agency (EMA) in 2012, followed by the approval for the treatment of ...
Ajayi, Stefanie, Becker, Heiko, Reinhardt, Heike, Engelhardt, Monika, Zeiser, Robert, Bubnoff, Nikolas von, Wäsch, Ralph   +6 more
openaire   +3 more sources

Ruxolitinib

Drugs, 2012
Ruxolitinib is a selective inhibitor of Janus kinases (JAK) 1 and 2, which are involved in the signalling pathway of various cytokines and growth factors essential to haematopoiesis. JAK 1 and 2 are implicated in the development of myelofibrosis, as well as other haematological malignancies.
Gillian M. Keating, Lily P. H. Yang
openaire   +3 more sources

Ruxolitinib

2014
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis, which is characterized, biologically, by the activation of the JAK-STAT pathway and, clinically, by bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality ...
Becker, Heiko, Engelhardt, Monika, Bubnoff, Nikolas von, Wäsch, Ralph   +3 more
openaire   +3 more sources

Ruxolitinib for the treatment of myelofibrosis

Drugs of Today, 2011
Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms. The suggested mechanism of action of ruxolitinib is attenuation of cytokine signaling via the inhibition of JAK1 and JAK2 (wild-
Srdan Verstovsek, Alen Ostojić, Radovan Vrhovac   +2 more
openaire   +3 more sources

New Indication for Ruxolitinib

AJN, American Journal of Nursing, 2022
The kinase inhibitor ruxolitinib (Jakafi) is now approved to treat chronic graft-vs-host disease.
openaire   +2 more sources